Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...

Vision shows floodwaters rising quickly on the Llano River, near Kingsland in Texas on Friday, July 4.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals (MDGL) stock and Viking Therapeutics (VKTX) stock gain after Altimmune's (ALT) trial setback for liver disease drug. Read more here.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

Find the latest Madrigal Pharmaceuticals, Inc. (MDGL) stock quote, history, news and other vital information to help you with your stock trading and investing.

QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

Short interest in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) increased during the last reporting period, rising from 4.03M to 4.10M. This put 21.43% of the company's publicly available shares ...